Systemic Treatments for Type 2 Inflammation
Explore new systemic treatments for type 2 inflammation in atopic dermatitis, including lebrikizumab, nemolizumab, upadacitinib, and dupilumab. Learn how these therapies target key cytokines, improve skin clearance, and enhance patient outcomes.
Lauren McGrath is a research fellow for the Center for Dermatology Research and Center for Translational Dermatology at Wake Forest Dermatology.
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of The Dermatologist or HMP Global, their employees, and affiliates.
The APP Institute is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of patient care across the spectrum of dermatology.
The APP Institute | Dermatology is designed for Advanced Practice Providers who specialize in Dermatology, to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods, while remaining focused on the fundamental principles and terminology associated with Dermatology. Engage year-round with the Dermatology Learning Network to access clinical insights, interactive features, research news updates, accredited continuing education programs, and more.
